The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of response and survival in Allovectin melanoma trials.
D. D. Kharkevitch
Employment or Leadership Position - Vical
Stock Ownership - Vical
A. Chu
Employment or Leadership Position - Vical
Stock Ownership - Vical
L. G. Strause
Employment or Leadership Position - Vical
Stock Ownership - Val-Pharma
L. R. Muenz
Consultant or Advisory Role - Vical
R. T. Kenney
Employment or Leadership Position - Vical
Stock Ownership - Val-Pharma
A. Rolland
Employment or Leadership Position - Vical
Stock Ownership - Vical